Marinus Pharmaceuticals Inc (MRNS)
0.3351
+0.01
(+2.20%)
USD |
NASDAQ |
Nov 04, 16:00
0.3227
-0.01
(-3.70%)
After-Hours: 20:00
Marinus Pharmaceuticals Revenue (Quarterly): 8.056M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 8.056M |
March 31, 2024 | 7.679M |
December 31, 2023 | 7.19M |
September 30, 2023 | 7.338M |
June 30, 2023 | 6.081M |
March 31, 2023 | 10.38M |
December 31, 2022 | 7.162M |
September 30, 2022 | 2.34M |
Date | Value |
---|---|
June 30, 2022 | 1.79M |
March 31, 2022 | 14.19M |
December 31, 2021 | 1.52M |
September 30, 2021 | 10.11M |
June 30, 2021 | 1.905M |
March 31, 2021 | 1.806M |
December 31, 2020 | 1.547M |
September 30, 2020 | 0.171M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.171M
Minimum
Sep 2020
14.19M
Maximum
Mar 2022
5.579M
Average
6.622M
Median
Revenue (Quarterly) Benchmarks
Chimerix Inc | 0.129M |
Cellectar Biosciences Inc | -- |
Ocular Therapeutix Inc | 16.44M |
Viking Therapeutics Inc | -- |
Jaguar Health Inc | 2.721M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -35.83M |
Total Expenses (Quarterly) | 38.34M |
EPS Diluted (Quarterly) | -0.63 |
Enterprise Value | 10.41M |
Gross Profit Margin (Quarterly) | 90.88% |
Profit Margin (Quarterly) | -444.7% |
Earnings Yield | -793.8% |
Normalized Earnings Yield | -783.60 |